Patents by Inventor Nobufusa Serizawa
Nobufusa Serizawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6972323Abstract: Anti-Fas antibodies which are cross-reactive with mouse and human Fas and are useful in the treatment of conditions attributable to abnormalities in the Fas/Fas ligand system.Type: GrantFiled: February 9, 2000Date of Patent: December 6, 2005Assignee: Sankyo Company, LimitedInventors: Nobufusa Serizawa, Kimihisa Ichikawa, Jun Ohsumi, Masahiko Ohtsuki, Hideyuki Haruyama, Tohru Takahashi, Hiroko Yoshida, Akio Shiraishi, Shin Yonehara
-
Patent number: 6746673Abstract: A pharmaceutical composition containing an anti-human Fas antibody having apoptosis inducing activity and a compound having a folate antagonist activity or a dihydrofolate reductase inhibiting activity, as active ingredients for the prophylaxis and/or treatment of an autoimmune disease or rheumatoid arthritis. According to the present invention, the amount of the anti-Fas antibody to be used can be reduced and thereby the possibility that a patient may become tolerant to anti-Fas antibody as a result of the production of antibodies against the anti-Fas antibody in the patient's body or the like can be decreased, and thus is provided a pharmaceutical composition which can be used for a long time.Type: GrantFiled: November 20, 2001Date of Patent: June 8, 2004Assignee: Sankyo Company, LimitedInventors: Nobufusa Serizawa, Kimihisa Ichikawa, Hiroko Yoshida
-
Patent number: 6743611Abstract: The present invention provides expression systems for exogenous polypeptides wherein the polypeptide is expressed as a fusion protein together with clover yellow virus Nuclear Inclusion a (NIa), the NIa component serving to autolyze the fusion protein after expression. This system can be used to express a novel polypeptide which we have designated KM31-7 protein and which is capable of reducing dichloroindophenol and reduced glutathione. This polypeptide is useful in the treatment of disorders caused by oxidative stress.Type: GrantFiled: April 25, 2001Date of Patent: June 1, 2004Assignee: Sankyo Company, LimitedInventors: Tohru Takahashi, Nobufusa Serizawa, Ryuta Koishi, Ichiro Kawashima
-
Publication number: 20030176688Abstract: The present invention provides expression systems for exogenous polypeptides wherein the polypeptide is expressed as a fusion protein together with clover yellow virus Nuclear Inclusion a (NIa), the NIa component serving to autolyze the fusion protein after expression. This system can be used to express a novel polypeptide which we have designated KM31-7 protein and which is capable of reducing dichloroindophenol and reduced glutathione. This polypeptide is useful in the treatment of disorders caused by oxidative stress.Type: ApplicationFiled: April 25, 2001Publication date: September 18, 2003Applicant: SANKYO COMPANY, LIMITEDInventors: Tohru Takahashi, Nobufusa Serizawa, Ryuta Koishi, Ichiro Kawashima
-
Publication number: 20030170817Abstract: Anti-Fas antibodies which are cross-reactive with mouse and human Fas and are useful in the treatment of conditions attributable to abnormalities in the Fas/Fas ligand system.Type: ApplicationFiled: February 5, 2003Publication date: September 11, 2003Applicant: SANKYO COMPANY, LIMITEDInventors: Nobufusa Serizawa, Kimihisa Ichikawa, Jun Ohsumi, Masahiko Ohtsuki, Hideyuki Haruyama, Tohru Takahashi, Hiroko Yoshida, Akio Shiraishi, Shin Yonehara, Kaori Nakahara, Ikuko Tamaki
-
Publication number: 20030103976Abstract: Anti-Fas antibodies which are cross-reactive with mouse and human Fas and are useful in the treatment of conditions attributable to abnormalities in the Fas/Fas ligand system.Type: ApplicationFiled: August 9, 2002Publication date: June 5, 2003Applicant: Sankyo Company, LimitedInventors: Nobufusa Serizawa, Kimihisa Ichikawa, Jun Ohsumi, Masahiko Ohtsuki, Hideyuki Haruyama, Tohru Takahashi, Hiroko Yoshida, Akio Shiraishi, Shin Yonehara, Kaori Nakahara, Ikuko Tamaki
-
Publication number: 20020103212Abstract: A pharmaceutical composition containing an anti-human Fas antibody having apoptosis inducing activity and a compound having a folate antagonist activity or a dihydrofolate reductase inhibiting activity, as active ingredients for the prophylaxis and/or treatment of an autoimmune disease or rheumatoid arthritis. According to the present invention, the amount of the anti-Fas antibody to be used can be reduced and thereby the possibility that a patient may become tolerant to anti-Fas antibody as a result of the production of antibodies against the anti-Fas antibody in the patient's body or the like can be decreased, and thus is provided a pharmaceutical composition which can be used for a long time.Type: ApplicationFiled: November 20, 2001Publication date: August 1, 2002Applicant: SANKYO COMPANY, LIMITEDInventors: Nobufusa Serizawa, Kimihisa Ichikawa, Hiroko Yoshida, Setsu Serizawa
-
Patent number: 6307038Abstract: The present invention provides expression systems for exogenous polypeptides wherein the polypeptide is expressed as a fusion protein together with clover yellow virus Nuclear Inclusion a (NIa), the NIa component serving to autolyze the fusion protein after expression. This system can be used to express a novel polypeptide which we have designated KM31-7 protein and which is capable of reducing dichloroindophenol and reduced glutathione. This polypeptide is useful in the treatment of disorders caused by oxidative stress.Type: GrantFiled: October 6, 1998Date of Patent: October 23, 2001Assignee: Sankyo Company, LimitedInventors: Tohru Takahashi, Nobufusa Serizawa, Ryuta Koishi, Ichiro Kawashima
-
Patent number: 5955072Abstract: The present invention provides expression systems for exogenous polypeptides wherein the polypeptide is expressed as a fusion protein together with clover yellow virus Nuclear Inclusion a (NIa), the NIa component serving to autolyze the fusion protein after expression. This system can be used to express a novel polypeptide which we have designated KM31-7 protein and which is capable of reducing dichloroindophenol and reduced glutathione. This polypeptide is useful in the treatment of disorders caused by oxidative stress.Type: GrantFiled: July 11, 1995Date of Patent: September 21, 1999Assignee: Sankyo Company, LimitedInventors: Tohru Takahashi, Nobufusa Serizawa, Ryuta Koishi, Ichiro Kawashima
-
Patent number: 5830695Abstract: A 1 kbp length of the 5'-noncoding region of the gene encoding cytochrome P-450.sub.sca-2 in the actinomycete Streptomyces carbophilus has transcription promoter activity which is substrate inducible. When the 1 kbp region is shortened, transcription activity becomes constitutive and the shortened promoters can be used advantageously in expression systems, especially those expressing P-450.sub.sca-2 in the presence of ML-236B to produce pravastatin sodium.Type: GrantFiled: November 27, 1996Date of Patent: November 3, 1998Assignee: Sankto Company, LimitedInventors: Nobufusa Serizawa, Ichiro Watanabe
-
Patent number: 5827855Abstract: Compounds of formula (I): ##STR1## wherein R.sup.1 represents a group of formula (II) or (III): ##STR2## R.sup.2 is alkyl, alkenyl or alkynyl; R.sup.3 and R.sup.4 are each hydrogen, alkyl, alkenyl or alkynyl; R.sup.5 is hydrogen or a carboxy-protecting group; R.sup.a is a group of formula --OR.sup.6 ; R.sup.6 is hydrogen; R.sup.6a and R.sup.6b are each hydrogen, a hydroxy-protecting group, alkyl, alkanesulfonyl, halogenated alkanesulfonyl or arysulfonyl, and their salts and esters. Such compounds inhibit the synthesis of cholesterol, and can be used for the treatment and prophylaxis of hypercholesterolemia and of various cardiac disorders.Type: GrantFiled: December 28, 1995Date of Patent: October 27, 1998Assignee: Sankyo Company, LimitedInventors: Hiroshi Kogen, Sadao Ishihara, Teiichiro Koga, Eiichi Kitazawa, Nobufusa Serizawa, Kiyoshi Hamano
-
Patent number: 5491167Abstract: Compounds of formula (I): ##STR1## and their salts and esters have the ability to inhibit the synthesis of cholesterol, and can thus be used for the treatment and prophylaxis of hypercholesterolemia and of various cardiac disorders.Type: GrantFiled: January 31, 1994Date of Patent: February 13, 1996Assignee: Sankyo Company, LimitedInventors: Sadao Ishihara, Hiroshi Kogen, Teiichiro Koga, Eiichi Kitazawa, Nobufusa Serizawa
-
Patent number: 5451688Abstract: Compounds of formula (I): ##STR1## [wherein R.sup.1 represents a group of formula (II) or (III): ##STR2## R.sup.2 is alkyl, alkenyl or alkynyl; R.sup.3 and R.sup.4 are each hydrogen, alkyl, alkenyl or alkynyl; R.sup.5 is hydrogen or a carboxy-protecting group; R.sup.a is hydrogen or a group of formula and --OR.sup.6 ; R.sup.6, R.sup.6a and R.sup.6b are each hydrogen, a hydroxy-protecting group, alkyl, alkanesulfonyl, halogenated alkanesulfonyl or arylsulfonyl] and their salts and esters have the ability to inhibit the synthesis of cholesterol, and can thus be used for the treatment and prophylaxis of hypercholesterolemia and of various cardiac disorders.Type: GrantFiled: December 28, 1993Date of Patent: September 19, 1995Assignee: Sankyo Company, LimitedInventors: Hiroshi Kogen, Sadao Ishihara, Teiichiro Koga, Eiichi Kitazawa, Nobufusa Serizawa, Kiyoshi Hamano
-
Patent number: 5407826Abstract: Trans-4-hydroxy-L-proline is produced microbially, especially by the cultivation of a microorganism of the genus Clonostachys, Gliocladium or Nectria.Type: GrantFiled: March 22, 1994Date of Patent: April 18, 1995Assignee: Sankyo Company, LimitedInventors: Tatsuji Matsuoka, Nobufusa Serizawa, Tsuyoshi Hosoya, Kouhei Furuya
-
Patent number: 5334517Abstract: Trans-4-hydroxy-L-proline is produced microbially, especially by the cultivation of a microorganism of the genus Clonostachys, Gliocladium or Nectria.Type: GrantFiled: December 15, 1992Date of Patent: August 2, 1994Assignee: Sankyo Company LimitedInventors: Tatsuji Matsuoka, Nobufusa Serizawa, Tsuyoshi Hosoya, Kouhei Furuya